Compare Incyte Corporation (INCY) vs NICE Ltd (NICE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs NICE Ltd — how do they compare? Incyte Corporation trades at $120.51 (market cap $24.54B), while NICE Ltd trades at $97.81 (market cap $6.02B). The key difference: Incyte Corporation is far larger — about 4.1× NICE Ltd's market cap, and Incyte Corporation is trading nearer its 52-week high, NICE Ltd nearer its low. Which is the better fit depends on your goals.
| INCY | NICE | |
|---|---|---|
Market Cap | $24.54B | $6.02B |
Sector | Health | Technology |
52-Week High | $129.93 | $153.44 |
52-Week Low | $81.61 | $83.15 |
Enterprise Value | $20.04B | $5.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
NICE stock trades at $98.71, down 3.76% today, but maintains a bullish technical outlook with support near $99. The company reported Q2 2026 earnings beats, with revenue growth of 7.6% year-over-year to $782.3 million (Business Wire, 2026-08-05). Valuation metrics appear reasonable with a P/E of 14.8 and P/S of 2.03. Recent news highlights partnerships with Currys and RingCentral to enhance AI-driven customer engagement.
The investment outlook is positive, supported by strong analyst consensus with a $115 price target (52% buy ratings). Key opportunities include cloud and AI growth, while risks involve execution challenges and potential margin pressure from increased investments. The stock offers ~16.5% upside to the consensus target, but investors should monitor Q3 2026 earnings due to expected EPS of 2.76.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
